查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1471974

基因治疗市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按载体、适应症​​、交付模式和地理位置

Gene Therapy Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Vectors, Indication, Delivery Mode, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

基因治疗市场规模预计将从2023年的51.1亿美元成长到2031年的256.9亿美元；预计 2023 年至 2031 年复合年增长率为 14.3%。

基因疗法是利用基因治疗疾病的开创性治疗方法。基因疗法透过将遗传物质引入患者的细胞来替换或纠正异常基因，为治疗和治癒疾病提供了一种有前途的方法。基因治疗可分为体内基因治疗及离体基因治疗。这种创新的治疗方法近年来获得了极大的关注和投资，导致基因治疗技术和技术的进步。基因治疗市场的成长归因于遗传疾病负担的增加以及 FDA 批准基因治疗的数量不断增加。然而，基因治疗产品的高成本阻碍了基因治疗市场的成长。

研究人员正在致力于将基因疗法应用于临床。各大学和研究所正在开发各种产品组合，预计在预测期内创造收入将会增加。在FDA 批准第一个基因疗法后，基因疗法的临床试验数量从2017 年到2018 年急剧增加。 。在预测期内，预计强劲的产品线将为基因治疗市场的成长提供新的机会。

基于向量的见解

根据载体，基因治疗市场分为非病毒载体和病毒载体。到 2023 年，病毒载体细分市场将占据重要的基因治疗市场。病毒载体能够将遗传物质有效地递送至目标细胞。它们源自于自然可以感染细胞并转移其遗传物质的病毒。这使得它们能够非常有效地将治疗基因传递到患者的细胞中。此外，病毒载体具有高水准的特异性和选择性。它们可以被设计为针对特定类型的细胞或组织，从而实现治疗基因的标靶递送。这在基因治疗中尤其重要，因为它降低了脱靶效应的风险并提高了治疗的有效性。此外，多年来，病毒载体经过广泛的研究和优化，导致了更安全、更有效的载体系统的开发。载体设计和製造技术的进步提高了病毒载体的安全性和可扩展性，使其更适合临床应用。

根据 ClinicalTrials.gov 的分析，约 58% 正在开发的基因疗法使用病毒载体。用于基因治疗的最常用病毒载体是腺相关病毒，因为它能够将基因递送至非分裂细胞，在非分裂细胞中该基因具有长期治疗作用。不同种类的腺相关病毒针对不同的细胞，使它们成为遗传物质到体内所需位置的合适转运体，从而提供客製化的治疗。此外，病毒载体表现出低免疫原性、安全性和长期瞬时表达。总体而言，对安全有效的基因治疗的需求不断增长，加上病毒载体提供的优势，促进了该领域的显着增长，对基因治疗市场的增长产生了积极影响。

美国食品药物管理局、世界卫生组织和疾病管制与预防中心是准备基因疗法市场报告时参考的主要和次要来源之一。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：基因治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：基因治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：基因治疗市场 - 全球市场分析

  • 基因治疗 - 全球市场概览
  • 基因治疗 - 全球市场与 2031 年预测

第 7 章：基因治疗市场 - 收入分析 - 按向量类型，2021-2031

  • 概述
  • 病毒载体
  • 非病毒载体

第 8 章：基因治疗市场 - 收入分析 - 依方法，2021-2031

  • 概述
  • 离体
  • 体内

第 9 章：基因治疗市场 - 收入分析 - 按应用划分，2021-2031 年

  • 概述
  • 神经系统疾病
  • 癌症
  • 杜氏肌肉营养不良症
  • 肝病
  • 其他适应症

第 10 章：基因治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：基因治疗市场 - 主要公司概况

  • Novartis AG
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Bluebird Bio Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Daiichi Sankyo
  • CSL Behring
  • Biogen
  • Oxford Biomedica

第 14 章：附录

简介目录
Product Code: TIPHE100001165

The gene therapy market size is expected to grow from US$ 5.11 billion in 2023 to US$ 25.69 billion by 2031; it is projected to register a CAGR of 14.3% during 2023-2031.

Gene therapy is a pioneering treatment method that uses genes to treat diseases. Gene therapy offers a promising approach to treat and cure diseases by introducing genetic material into a patient's cells to replace or correct abnormal genes. Gene therapy can be classified into in-vivo and ex-vivo gene therapy. This innovative treatment method has gained significant attention and investment in recent years, leading to advancements in gene therapy techniques and technologies. The gene therapy market growth is attributed to the increasing burden of genetic diseases and the rising number of FDA approvals of gene therapies. However, the high cost of gene therapy products hinders the growth of the gene therapy market.

Researchers are working on making gene therapy available in clinics. A wide range of product portfolios are in the pipeline at various universities and institutes, and revenue generation is expected to increase during the forecast period. Following the FDA's approval of the first gene therapy, the number of clinical trials for gene therapy surged dramatically from 2017 to 2018. About 1,986 products, including CAR T-cell treatments and other genetically engineered cell therapies, are currently under development, according to the American Society of Gene & Cell Therapy. Over the projection period, the robust pipeline is anticipated to offer new opportunities for the growth of the gene therapy market.

Vectors-Based Insights

Based on vectors, the gene therapy market is categorized into non-viral vectors and viral vectors. The viral vectors segment held a significant gene therapy market share in 2023. It is anticipated to record a higher CAGR in the market during the forecast period. Viral vectors have the ability to competently deliver genetic material into target cells. They are derived from viruses that naturally can infect cells and transfer their genetic material. This makes them highly effective in delivering therapeutic genes into the cells of patients. In addition, viral vectors offer a high level of specificity and selectivity. They can be engineered to target particular types of cells or tissues, allowing for targeted delivery of therapeutic genes. This is particularly important in gene therapy, as it reduces the risk of off-target effects and enhances the effectiveness of the treatment. Moreover, viral vectors have been extensively studied and optimized over the years, leading to the development of safer and more efficient vector systems. Advances in vector design and manufacturing technologies have improved the safety profile and scalability of viral vectors, making them more suitable for clinical applications.

According to the analysis from clinicaltrials.gov, ~58% of gene therapies under development are using viral vectors. The most commonly employed viral vector for gene therapy is adeno-associated virus, owing to its ability to deliver genes to non-dividing cells where the gene has a long-term therapeutic impact. Different varieties of adeno-associated viruses target different cells, making them a suitable transporter of genetic material to desired locations inside the body, providing a customized treatment. In addition, viral vectors display low immunogenicity, safety, and long-term transient expression. Overall, the growing demand for safe and effective gene therapies, along with the advantages offered by viral vectors, has contributed to the segment's significant growth, positively influencing the gene therapy market growth.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the gene therapy market report.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Gene Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Gene Therapy Market - Global Market Analysis

  • 6.1 Gene Therapy - Global Market Overview
  • 6.2 Gene Therapy - Global Market and Forecast to 2031

7. Gene Therapy Market - Revenue Analysis (USD Million) - By Vector Type, 2021-2031

  • 7.1 Overview
  • 7.2 Viral Vector
  • 7.3 Non-Viral Vector

8. Gene Therapy Market - Revenue Analysis (USD Million) - By Method, 2021-2031

  • 8.1 Overview
  • 8.2 Ex-Vivo
  • 8.3 In-Vivo

9. Gene Therapy Market - Revenue Analysis (USD Million) - By Application, 2021-2031

  • 9.1 Overview
  • 9.2 Neurological Disorders
  • 9.3 Cancer
  • 9.4 Duchenne Muscular Dystrophy
  • 9.5 Hepatological Diseases
  • 9.6 Other Indications

10. Gene Therapy Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Gene Therapy Market Overview
    • 10.1.2 North America Gene Therapy Market Revenue and Forecasts to 2031
    • 10.1.3 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Vector Type
    • 10.1.4 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Method
    • 10.1.5 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Application
    • 10.1.6 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Gene Therapy Market
        • 10.1.6.1.1 United States Gene Therapy Market, by Vector Type
        • 10.1.6.1.2 United States Gene Therapy Market, by Method
        • 10.1.6.1.3 United States Gene Therapy Market, by Application
      • 10.1.6.2 Canada Gene Therapy Market
        • 10.1.6.2.1 Canada Gene Therapy Market, by Vector Type
        • 10.1.6.2.2 Canada Gene Therapy Market, by Method
        • 10.1.6.2.3 Canada Gene Therapy Market, by Application
      • 10.1.6.3 Mexico Gene Therapy Market
        • 10.1.6.3.1 Mexico Gene Therapy Market, by Vector Type
        • 10.1.6.3.2 Mexico Gene Therapy Market, by Method
        • 10.1.6.3.3 Mexico Gene Therapy Market, by Application

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Gene Therapy Market - Key Company Profiles

  • 13.1 Novartis AG
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Astellas Pharma Inc
  • 13.3 Bristol-Myers Squibb Company
  • 13.4 Bluebird Bio Inc.
  • 13.5 Sanofi
  • 13.6 F. Hoffmann-La Roche Ltd.
  • 13.7 Daiichi Sankyo
  • 13.8 CSL Behring
  • 13.9 Biogen
  • 13.10 Oxford Biomedica

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud